Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc.
Cellectar will have the right to globally develop and commercialize any OHPAS containing PDC.
- Cellectar will have the right to globally develop and commercialize any OHPAS containing PDC.
- Since initiating our multi-target collaboration, Cellectar has been able to advance various PDC candidates which leverage the differentiated advantages of IntoCells technology, said James Caruso, president and CEO of Cellectar.
- We have built a strong partnership with Cellectar through the multi-target PDC platform collaboration.
- This validation has led to the expansion of our collaboration, said Tae Kyo Park, Founder and CEO of IntoCell.